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Background: In the WHO 2010 classification, the neuroendocrine tumors (NETs) are subdivided by their mitotic
index or Ki67 index into either G1 or G2 NETs. Tumors with a Ki67 index of <2% are classified as G1 and those with
3—20% are classified as G2. However, the assessment of tumors with Ki67 index of greater than 2% and less than
or equal to 3% is still unclear. To resolve the problem, we validated the Ki67 index criteria of gastrointestinal NETs
of the WHO 2010 classification.
Methods: The medical records of 45 patients who were pathologically diagnosed as having NET G1/G2 of the
gastrointestinal tract were analyzed retrospectively. According to the WHO 2010 classification, Ki67 index were
calculated. Computer-assisted cytometrical analysis of Ki67 immunoreactivity was performed using the WinRooF
image processing software. Receiver operating characteristic (ROC) curves were generated to determine the best
discriminating Ki67 index. To clarify the assessment of tumors with Ki67 index between 2—3%, the calculated cutoff
of Ki67 index was evaluated using Fisher’s exact test.
Results: ROC curve analysis confirmed that 2.8% was the best Ki67 index cutoff value for predicting metastasis or
recurrence. The sensitivity of the new Ki67 index cutoff was 42.9%, and the specificity was 86.8%.
Conclusions: Division of NETs into G1/G2 based on Ki67 index of 3% was appropriate to predict metastases or
recurrences. The WHO grading system may be the most useful classification to predict metastases or recurrences.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1553036118943799Background
Since S. Oberndorfer proposed the term “carcinoid” in
1907 [1], the origins of neuroendocrine tumors (NETs) of
the gastrointestinal tract as well as the malignancy of these
tumors have been attracting the attention of clinicians
[2-6]. After investigation by prognostic or diagnostic pro-
cedures, based on a wealth of evidence, the 2000 edition
of the World Health Organization (WHO) classification
provided a rational approach to the nomenclature and* Correspondence: t-fuji@dokkyomed.ac.jp
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distribution, and reproduction in any mediumclassification of NETs of the digestive system [7]. This
system identified NETs as well differentiated endocrine
tumors (WDET), well differentiated endocrine carcinomas
(WDEC), and poorly differentiated endocrine carcinomas
(PDEC) [8]. In 2010, a revised version of the WHO classi-
fication appeared. The new classification defines the entire
group of tumors as neuroendocrine neoplasms (NENs),
which have been confirmed to arise from the neuroendo-
crine cell system. NENs are shared with marker proteins
of neuroendocrine cell system [7,9,10], and they are fur-
ther categorized into neuroendocrine carcinomas (NECs)tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.diagnosticpathology.org/content/8/1/65and NETs. NECs are morphologically similar to small cell
carcinoma and large cell carcinoma of the lung, while
NETs encompass neoplasms that were previously termed
“carcinoid” or “atypical carcinoid” [7,9,10]. NETs are
subdivided by their mitotic index or Ki67 index into either
G1 or G2 NETs. This revised classification is a simple and
useful grading system based on the proliferative activity.
However, the assessment of tumors with Ki67 index of
greater than 2% and less than or equal to 3% is still
unclear. Despite this, due to large inter-observer differ-
ences in mitotic counts, the validity and reproducibility of
Ki67 index are clearly superior to those of the mitotic
index [11]. Tumors with a Ki67 index of <2% are classified
as G1 and those with 3—20% are classified as G2. The
aim of this study was to evaluate whether this grading sys-
tem can predict metastasis or recurrence, to validate the
Ki67 index criteria of gastrointestinal NETs of the WHO
2010 classification, and to especially clarify the uncertainty
in assessment of tumors with Ki67 index between 2—3%.
We performed computer-assisted cytometrical analysis of
Ki67 immunohistochemistry (IHC), which was established
in several of our past studies [12,13], using the WinRooF
image processing software (Mitani Corp., Tokyo, Japan).
Methods
Study cases and tissue samples
The medical records of 45 patients who were pathologic-
ally diagnosed as having NET G1/G2 of the gastrointes-
tinal tract were analyzed retrospectively. They were
diagnosed at Dokkyo Medical University and its associ-
ated institutions between January 2003 and June 2012.
Five cases were obtained by biopsy, 21 cases by endo-
scopic resection, and 19 cases by surgical resection. All
cases were re-diagnosed and classified according to the
criteria of the WHO 2010 classification. No case
contained adenomatous component or any other lesion
with NETs [14]. Cases with multiple tumors and tumors
arising from the appendix were excluded. Histological
diagnoses of all cases were confirmed by the pathological
report, and neuroendocrine differentiation was con-
firmed immunohistochemically using antibodies directed
against chromogranin A and synaptophysin. This study
was performed with the approval of the ethics commit-
tee of each institution, and informed consent was
obtained from all patients.
Immunohistochemical staining for Ki67
Immunohistochemical staining for Ki67 was performed with
a LSAB-2 kit (LSAB2 System-HRP; DAKO, Carpinteria,
CA, USA) as described previously [15,16]. The 4-μm thick
sections were placed on slides, deparaffinized, and
dehydrated. They were then placed in 0.01 M citrate buffer
(pH 6.0) and treated by microwave heating (400 W, 95°C;
MI-77; Azumaya, Tokyo, Japan) for 40 minutes to facilitateantigen retrieval. Then, the sections were pretreated with
0.3% H2O2 in methanol at room temperature to quench
endogenous peroxidase activity. This was followed by
blocking with Protein Block Serum-Free (Dako, USA)
for 30 minutes, and incubation with anti-Ki67 antibody
(1:50 clone MIB-1; Dako, Japan) for 1 hour. Thereafter,
the sections were incubated with biotinylated secondary
antibody for 15 minutes, washed with PBS, and treated
with peroxidase-conjugated streptavidin for 20 min. Fi-
nally, the sections were visualized by incubating in 3,
3′-diaminobenzidine tetrahydrochloride with 0.05%
H2O2 (Liquid DAB + Substrate Chromogen System;
Dako, USA) for 3 min and then counterstained with
Carazzi’s hematoxylin.Evaluation of immunohistochemical Ki67 expression
Stratified sampling procedure was performed according
to the WHO 2010 classification [17,18]. Ki67 indices
were calculated as a percentage of Ki67 positive cells in
500—2000 cells that were counted in areas of strongest
nuclear labeling (“hot spots”). Interactive virtual micros-
copy was performed to get standardized digital images
[19]. Images were captured at ×15—×30 magnification,
and computer-assisted cytometrical analysis of Ki67 im-
munoreactivity was performed using the WinRooF
image processing software (Mitani Corp., Tokyo, Japan)
[12,13,20-22]. In order to maximally differentiate the
target cells from the adjacent ones, the margins of the
nuclei were identified by enhanced contrast for RGB
separation (Figure 1). B (blue) image with the “Separate
Cells” function was the easiest to count Ki67 positive
cells, and R (red) image with the “Separate Circular
Figure” function was the easiest to count all tumor cells.
Size and shape of tumor cells was manually calibrated,
and the non-tumor cells were eliminated with a touch
pen by introducing a liquid crystal touch panel.Statistical analysis
Statistical analysis was performed using R (version 2.15.0).
For the analysis of risk factors for metastasis or recurrence,
sex, age, location of tumor, resection methods, size, Ki67
index, and grade of WHO classification were evaluated
using Fisher’s exact test or Welch two sample t-test. Re-
ceiver operating characteristic (ROC) curves were gener-
ated to determine the best discriminating tumor size and
Ki67 index. The cutoffs for predicting metastasis or recur-
rence by each component were defined by the values with
the highest accuracy that maximized the Youden index
(sensitivity + specificity-1) [23,24]. To clarify the assessment
of tumors with Ki67 index between 2—3%, the calculated
cutoff of the Ki67 index was evaluated using Fisher’s exact
test. Differences were considered to be statistically signifi-
cant when P <0.05.
Figure 1 Images of a case of NET. This case is rectal NET with multiple liver and lung metastasis, and its Ki67 index is 2.8%. A: Hematoxylin and
eosin staining. B: Immunohistochemical findings for Ki-67. C: Image of WinROOF. Count the Ki67 positive cells by B (blue) image of enhanced
contrast for RGB color separation. D: Image of WinROOF. Count all tumor cells by R (red) image of enhanced contrast for RGB color separation.
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Clinical characteristics
Among the 45 NET patients, seven cases (15.6%)
showed evidence of metastasis or recurrence. Three
patients had lymph node metastases, one had liver me-
tastases, one had liver and lymph node metastases, one
had liver and lung metastases, and another one had local
recurrence. All 45 patients were divided into two groups:
group A included those who had metastases or recur-
rences and group B were those who did not. There was
no difference between the two groups with respect to
the ratio of men to women, mean age, resection method,
invasion depth, and location of the primary tumor.
Metastases or recurrences occurred only from primary
duodenal (2 cases of 10, 20.0%) and rectal (5 cases of 29,
17.2%) tumors. The patient characteristics are outlined
in Table 1. ROC curve analysis confirmed that 20.5 mm
was the best tumor size cutoff value for predicting me-
tastasis or recurrence (area under the curve = 0.623).
The sensitivity of the analysis was 33.3%, and the specifi-
city was 100.0%. Although there was no difference be-
tween two groups with regard to mean tumor size, when
using this cutoff value, tumors larger than 20.5 mm were
predictive of metastasis or recurrence (p = 0.019).
Ki67 IHC in NET
No statistical difference was found between the two
groups with regard to mean Ki67 index (Group A: mean
2.83%, range 0.38—10.43%; Group B: mean 1.39%, range
0—6.44%). According to the WHO 2010 classification,
all cases were classified into G1 and G2 based on theKi67 index of 2% or 3% (Table 2), but there was no
difference. Therefore, to determine the best discriminat-
ing Ki67 index, ROC curve analysis was performed
(Figure 2), which determined that 2.8% was the best
Ki67 index cutoff value for predicting metastasis or
recurrence (area under the curve = 0.577). The sensitivity
of the new Ki67 index cutoff was 42.9%, and the specifi-
city was 86.8% (Table 3). Although there was no statis-
tical difference in the new cutoff value of Ki67 index,
compared with 2% (positive predictive value = 25.0%,
negative predictive value = 87.9%), the new cutoff (posi-
tive predictive value = 37.5%, negative predictive value =
89.2%) was more appropriate for prediction of metastasis
or recurrence. In clinical settings, a cutoff value of 3%
may be better for dividing the tumors into G1/G2. If the
cases were classified based on 3%, the sensitivity was
28.6% and the specificity was 89.5%.
Separating analysis by location of the primary tumor
Metastases or recurrences only occurred from primary
duodenal and rectal tumors, so the separating analysis
was performed according to each location. Among the
patients of NETs of the duodenum, 2 of 10 cases had
metastases or recurrences. Grade, tumor size, and inva-
sion depth were not predictive of metastasis or recur-
rence in this group (Table 4). In invasion deeper than
submucosa, duodenal NET G1 showed an equivalent
incidence of metastases as NET G2. On the other hand,
among the patients of rectal NET, 5 of 29 cases had me-
tastases or recurrences, and there were statistical differ-
ences in invasion depth and Ki67 index (Table 5).
Table 2 Analysis of Ki67 index, dividing into G1/G2 according
Metastas
+ (Group A, n = 7)
Mean Ki67 index (%) 2.83 (0.38—10.43)
Grade
G1 (Ki67 index ≦2%) 4
G2 (Ki67 index >2%) 3
Grade
G1 (Ki67 index ≦3%) 5
G2 (Ki67 index >3%) 2
Group A: the cases with metastases or recurrences.
Group B: the cases without metastases or recurrences.
Statistically significant difference (<0.05) by Fisher’s exact test or Welch two sample
Table 1 Clinical characteristics of patients with
neuroendocrine tumors
Metastases or recurrences
+ (Group A, n = 7) - (Group B, n = 38) p value
Gender 0.39
Male 4 28
Female 3 10
Mean age 58.4 (41—75) 61.9 (38—86) 0.50
Location 1
Stomach 0 4
Duodenum 2 (20.0%) 8
Small intestine 0 1
Colon 0 1
Rectum 5 (17.2%) 24
Tumor invasion 0.16
M 0 1
SM 4 28
MP 2 3
SS 1 1
Unknown 0 5
Resection
methods
0.34
Biopsy 0 5
Endoscopic
resection
2 19
Surgical
resection
5 14
Mean tumor size
(mm)
12.9 (3.5—27) 7.4 (1.5—15) 0.26
Group A: the cases with metastases or recurrences.
Group B: the cases without metastases or recurrences.
Statistically significant difference (<0.05) by Fisher’s exact test or Welch two
sample t-test.
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metastasis or recurrence, which was different from that
of NETs in the duodenum.
Discussion
S. Oberndorfer noted in 1907 that the multiple unusual
tumors in the small bowel were distinct clinical entities
and proposed the term “carcinoid” (“carcinoma-like”),
emphasizing in particular their benign features [1,2,25].
However, malignancy of this tumor group has been con-
firmed based on metastatic or survival rates in long term
studies [26-28]. Some studies have discussed the tumor
origins and suggested that these neoplasms may arise
from a type of endocrine cells, known as amine precur-
sor uptake and decarboxylation (APUD) cells [2-4]. Al-
though the APUD cells were initially suggested to be
derived from neural crest cells, it is now generally recog-
nized that gastroenteropancreatic APUD cells probably
arise from the endoderm [2,29]. Tumor definition was ini-
tially based on typical morphological characteristics, and
subsequent studies demonstrated argyrophilia-staining
properties of the tumors using silver impregnation tech-
niques, such as the Grimelius method [2,30-33]. More-
over, the neuroendocrine origin of the tumors was
definitively identified and assessed in detail using stains
for neuroendocrine differentiation markers, chromogranin
A, and/or synaptophysin [10,34]. After these investigations
by prognostic or diagnostic procedures, the term "carcin-
oid" has been regarded as a misnomer [28]. Since these
tumors are considered as cancers of the neuroendocrine
system, a more adequate term “neuroendocrine tumors” is
now widely used. Based on these lines of evidence, the
WHO 2000 classification provided a rational approach to
the nomenclature and classification of NETs of the digest-
ive system [7], which subdivided them into WDET,
WDEC, and PDEC [8]. NETs have historically been classi-
fied according to the foregut, midgut, or hindgut deriv-
ation, and they have been indicated the prognostic
differences. Some studies have also demonstrated theto the WHO 2010 classification
es or recurrences
- (Group B, n = 38) p value
1.39 (0—6.44) 0.35
29
9 0.36
34
4 0.23
t-test.
Figure 2 The ROC curve analysis to determine the best discriminating Ki67 index. Sens: sensitivity, Spec: specificity, PV+: positive predictive
value,PV-: negative predictive value.
Table 4 Separating analysis in the primary of duodenum
Metastases or recurrences
+ (Group A, n = 2) - (Group B, n = 8) p value
Mean tumor size
(mm)
15.5 (5—26) 7.63 (2—15) 0.59
Tumor invasion 1
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Since long-term follow up studies have indicated the
malignancy of these tumors, in 2010, a revised version of
the WHO classification appeared [7]. The new classifica-
tion defines the entire group of tumors as NENs, which
have been confirmed to arise from the neuroendocrine
cell system since they are shared with marker proteins of
this system [9,10]. NENs are further categorized into
NECs and NETs. NECs are morphologically similar to
small cell carcinoma and large cell carcinoma of the lung,
while NETs encompass neoplasms that were previously
termed “carcinoid” or “atypical carcinoid” [7,9,10]. The
NETs are subdivided by their mitotic index or Ki67 index
into either G1 or G2 NETs. This revised classification is a
simple and useful grading system based on the prolifera-
tive activity. However, the assessment of tumors with Ki67
index that is greater than 2% and less than or equal to 3%
is still unclear. Despite this, the inter-observer differences
in mitotic counts are larger than that of Ki67 index, andTable 3 Dividing by new cutoff value of Ki67 index
Metastases or recurrences
+ (Group A, n = 7) - (Group B, n = 38) p value
Ki67 index ≦2.8% 4 33
Ki67 index >2.8% 3 5 0.09
Group A: the cases with metastases or recurrences.
Group B: the cases without metastases or recurrences.
Statistically significant difference (<0.05) by Fisher’s exact test.moreover, it is difficult to scan routinely at least 50 high
power fields (HPFs) (1 HPF = 2 mm2), that is required in
the WHO 2010 classification for evaluation of the mitotic
index. Thus, the validity and reproducibility of Ki67 index
are superior to those of the mitotic index [11]. Tumors
with a Ki67 index of <2% are classified as G1 while those
of 3—20% are classified as G2. Because one cutoff value is
used to divide continuous values into two groups, we vali-
dated the Ki67 index criteria of gastrointestinal NETs of
the WHO 2010 classification with the aim of clarifying the
assessment of tumors with Ki67 index between 2—3%.
We performed computer-assisted cytometrical analysis ofM 0 1
SM 2 5
MP 0 2
SS 0 0
Mean Ki67 index (%) 0.56 (0.40—0.73) 1.55 (0.34—4.29) 1
Group A: the cases with metastases or recurrences.
Group B: the cases without metastases or recurrences.
Statistically significant difference (<0.05) by Fisher’s exact test or Welch two
sample t-test.
Table 5 Separating analysis in the primary of rectum
Metastases or recurrences
+ (Group A, n = 5) - (Group B, n = 24) p value
Mean tumor size
(mm)
11.5 (3.5—27) 7.11 (1.5—15) 0.13
Tumor invasion <0.01
M 0 0
SM 2 22
MP 2 0
SS 1 0
Un known 0 2
Mean Ki67 index
(%)
3.73 (0.38—10.44) 1.24 (0.22—6.44) 0.022
Group A: the cases with metastases or recurrences.
Group B: the cases without metastases or recurrences.
Statistically significant difference (<0.05) by Fisher’s exact test or Welch two
sample t-test.
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http://www.diagnosticpathology.org/content/8/1/65Ki67 IHC, which was established in several of our past
studies [12,13], using the WinRooF image processing soft-
ware. Although it was not considered generally, a con-
cordance study using other softwares indicated that digital
image analysis and manual count were highly concordant
and were acceptable standards for Ki67 assessment [21].
Furthermore, in our experience, the number of cells could
be more accurately and objectively counted with some
devices. In this study, several problems occurred which
were similar to those in our previous studies. One of them
was that the non-tumor cells, such as lymphocytes or
histocytes, occasionally showed positivity for Ki67. To
resolve this, the non-tumor cells were eliminated with a
touch pen by introducing a liquid crystal touch panel as
our previous reports. After that, we evaluated whether the
grading system could accurately predict metastasis or
recurrence. Our results confirmed that 2.8% (or approxi-
mately 3%) is the best Ki67 index cutoff value for
predicting metastasis or recurrence. If the cases were clas-
sified based on 3%, the sensitivity was 28.6% and the speci-
ficity was 89.5%, which is meaningful for predicting
metastasis or recurrence because of the high specificity.
On the other hand, due to the low sensitivity, metastases
may be observed not only in G2 but also in G1 regardless
of biological malignancy. In recent studies, the location of
the primary tumor, size, invasion depth, and multiplicity
of tumors were associated with metastasis or recurrence
[26,35], and in our study, it was confirmed that tumor size
was correlative. It was also reported that the presence of
Circulating Tumor Cells (CTCs) with cellular expression
of epithelial cell adhesion molecule (EpCAM) was more
predictive of clinical outcomes than the WHO grading
system [36]. However, the methods to isolate CTCs for
molecular characterization are still being developed, and
there are few studies regarding CTCs in patients with
NETs [36,37]. Thus, at present, the WHO grading systemmay be the most useful classification to predict metastasis
or recurrence. In summary, division of NETs into G1/G2
based on Ki67 index of 3% was appropriate to predict me-
tastasis or recurrence (positive predictive value = 33.3%,
negative predictive value = 87.2%). To the best of our
knowledge, this is the first study to validate the numerical
criteria of the WHO 2010 classification of NETs and to
indicate the appropriateness of the Ki67 index. Further
investigation is required in order to support this finding.
Conclusions
ROC curve analysis confirmed that 2.8% is the best Ki67
index cutoff value for predicting metastases or recur-
rences. Division of NETs into G1/G2 based on Ki67
index of 3% was appropriate to predict metastases or
recurrences. The WHO grading system may be the most
useful classification to predict metastases or recurrences
thus far.
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